Bioequivalence study between two fluticasone propionate 250μg/salmeterol 50μg inhalation powders

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505198-34-00

Acronym

BECRO/RESP/AEROPK250

Enrollment

Registered

2023-07-26

Start date

2023-07-31

Completion date

2024-03-22

Last updated

2023-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers.Regular treatment of bronchial asthma, where a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) is indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. •Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Countries

Greece

Outcome results